Altogether, these data demonstrate that NASPA is an efficient and cost-effective platform that can utilize different large ‘bulky’ NA active site inhibitors to profile NA antigenicity and NAI antibody responses, making it well suited to aid the development of new influenza vaccines containing NA. The gene discussed is XK; the disease is influenza.